Unico Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-01-2025
- Paid Up Capital ₹ 0.30 M
as on 03-01-2025
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -9.86%
(FY 2022)
- Profit 13.32%
(FY 2022)
- Ebitda 21.45%
(FY 2022)
- Net Worth 86.43%
(FY 2022)
- Total Assets 95.86%
(FY 2022)
About Unico Pharma
The Corporate was formerly known as Vedanta Health Care Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Vishal Jaiswal, Ritweek Gupta, and Ritu Jaiswal serve as directors at the Company.
- CIN/LLPIN
U74920UP2014PTC065325
- Company No.
065325
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Unico Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Jaiswal  | Managing Director | 18-May-2015 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ritweek Gupta | Director | 06-Aug-2014 | Current |
| Ritu Jaiswal | Director | 06-Aug-2014 | Current |
Financial Performance of Unico Pharma.
Unico Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 9.86% decrease. The company also saw a substantial improvement in profitability, with a 13.32% increase in profit. The company's net worth Soared by an impressive increase of 86.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unico Pharma?
In 2022, Unico Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vedanta Hospital & Research Centre Private LimitedActive 12 years 9 monthsVishal Jaiswal and Ritweek Gupta are mutual person
- Darpan Diagnostic Centre Private LimitedActive 11 years 5 months
Vishal Jaiswal and Ritweek Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unico Pharma?
Unlock and access historical data on people associated with Unico Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unico Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unico Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
